RxDoctor Payments Data

Ellis Malone, MD

Internal Medicine · Austell, GANPI 1326037821

Payments from drug & device makers

$4,331in general payments, 2019–2025

Across 248 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$716
  • AstraZeneca$360
  • Lilly USA, LLC$295
  • Astellas Pharma US Inc$294
  • Pfizer$269
  • AbbVie$266
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$4,331100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,331 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$82,279
Medicare patients
282
Services billed
1,041

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin71$86,945
OzempicSemaglutide62$67,015
EliquisApixaban63$66,274
FarxigaDapagliflozin Propanediol52$57,972
MounjaroTirzepatide20$30,467
TrulicityDulaglutide21$27,668
LinzessLinaclotide34$25,412
MyrbetriqMirabegron37$22,211
XareltoRivaroxaban21$20,921
JanuviaSitagliptin Phosphate15$16,973
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,871
Tresiba Flextouch U-200Insulin Degludec11$10,558
Breo ElliptaFluticasone/Vilanterol15$10,525
BelbucaBuprenorphine Hcl11$10,270
Advair HfaFluticasone Propion/Salmeterol13$6,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$178$86,94571 claims
Novo NordiskOzempic$716$67,01562 claims
PfizerEliquis$269$66,27463 claims
Lilly USA, LLCMounjaro, Trulicity$295$58,13541 claims
AstraZenecaFarxiga$360$57,97252 claims
AbbVieLinzess, Synthroid$266$26,92150 claims
GSKTrelegy Ellipta, Breo Ellipta$250$26,39631 claims
Astellas Pharma US IncMyrbetriq$294$22,21137 claims
Johnson & JohnsonXarelto$27$20,92121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Austell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →